Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report
https://doi.org/10.17650/1994-4098-2019-15-1-73-77
Abstract
High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20–40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the recent literature and the case of durable partial response on pembrolizumab immunotherapy in a patient with a metastatic endometrioid adenocarcinoma with MMR-deficiency progressed on 2 chemotherapy lines. Partial response was achieved after 6th course, treatment was stopped after 8th course. Patient is on follow-up without any anticancer treatment for 11 months. Partial response lasts for 13 months, with further reduction in tumor size. The treatment was well tolerated without adverse events.
About the Authors
T. T. Andabekov
LLC “AV medical group”
Russian Federation
Russian Federation
Build. 1, 18, Turistskaya St., Saint Petersburg 197082
M. K. Rodina
LLC “AV medical group”
Russian Federation
Russian Federation
Build. 1, 18, Turistskaya St., Saint Petersburg 197082
G. A. Raskin
A.M. Granov Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of Russia;
Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia;
Saint Petersburg State University
Russian Federation
Russian Federation
Medical Faculty, Saint Petersburg State University
70 Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758,
2–4 Ligovskiy prospekt, Saint Petersburg 191036,
7–9 Universitetskaya naberezhnaya, Saint Petersburg 199034
K. G. Cham
A.M. Granov Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of Russia
Russian Federation
Russian Federation
70 Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
I. O. Rutkin
A.M. Granov Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of Russia
Russian Federation
Russian Federation
70 Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
References
1. Murali R., Soslow R.A., Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014;15(7):e268–78. DOI: 10.1016/S1470-2045(13)70591-6.
2. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5): E359–86. DOI: 10.1002/ijc.29210.
3. Liu F.S. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 2007;46:26–32.
4. Tinelli A., Mezzolla V., Leo G. et al. Microsatellite instability (MSI) as genomic markers in endometrial cancer: toward scientific evidences. Mini Rev Med Chem 2010;10:1356–65.
5. Weigelt B., Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol 2012;24:554–63. DOI: 10.1097/CCO.0b013e328354e585.
6. Kunitomi H., Banno K., Yanokura M. et al. New use of microsatellite instability analysis in endometrial cancer. Oncol Lett 2017;14(3):3297–301. DOI: 10.3892/ol.2017.6640.
7. Zaanan A., Meunier K., Sangar F. et al. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. Cell Oncol (Dordr) 2011;34:155–76.
8. Karamurzin Y., Zeng Z., Stadler Z.K. et al. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol 2012;43:1677–87. DOI: 10.1016/j.humpath.2011.12.012.
9. Lawes D.A., SenGupta S., Boulos P.B. The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur J Surg Oncol 2003;29(3):201–12.
10. Ligtenberg M.J., Kuiper R.P., Chan T.L. et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1. Nat Genet 2009;41(1):112–7.
11. Meyer L.A., Broaddus R.R., Lu K.H. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009;16:14–22.
12. Leenen C.H., van Lier M.G., van Doorn H.C. et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤70 years. Gynecol Oncol 2012;125:414–20. DOI: 10.1016/j.ygyno.2012.01.049.
13. Ta R.M., Hecht J.L., Lin D.I. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. Gynecol Oncol 2018;151(3):401– 6. DOI: 10.1016/j.ygyno.2018.10.012.
14. Luchini C., Bibeau F., Ligtenberg M.J.L. et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 2019;0:1–12. DOI: 10.1093/annonc/mdz116.
15. Le D.T., Uram J.N., Wang H. et al. PD-1 Blockade in tumors with mismatchrepair deficiency. N Engl J Med 2015;372(26):2509–20. DOI: 10.1056/NEJMoa1500596.
Review
For citations:
Andabekov T.T., Rodina M.K., Raskin G.A., Cham K.G., Rutkin I.O. Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report. Tumors of female reproductive system. 2019;15(1):73-77. (In Russ.) https://doi.org/10.17650/1994-4098-2019-15-1-73-77
Views:
936
Email this article 